Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reinventing biotech systems for patient impact.

Nature medicine·2026
Same author

Follow the data: tracking data quality and completeness in oncology real-world data.

JAMIA open·2026
Same author

Physical Activity and Stroke Incidence among Postmenopausal Women: Insights from the Women's Health Initiative.

Neuroepidemiology·2025
Same author

Advancing Decentralized and Pragmatic Clinical Trials as a Path Toward Improved Representativeness and Greater Generalizability of Clinical Trial Evidence.

Clinical therapeutics·2025
Same author

Addressing the challenges of integrating digital health technologies to measure patient-centred outcomes in clinical registries.

The Lancet. Digital health·2024
Same author

Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.

JAMA·2024

Related Experiment Video

Updated: May 23, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Data for cancer comparative effectiveness research: past, present, and future potential.

Anne-Marie Meyer1, William R Carpenter, Amy P Abernethy

  • 1Universisty of North Carolina-Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Cancer
|April 21, 2012
PubMed
Summary

Comparative Effectiveness Research (CER) accelerates evidence generation in cancer care. Overcoming challenges requires multidisciplinary collaboration and improved data standards for wider acceptance and implementation.

Related Experiment Videos

Last Updated: May 23, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Area of Science:

  • Health Services Research
  • Cancer Research
  • Biostatistics

Background:

  • Comparative Effectiveness Research (CER) rapidly generates scientific evidence, addressing knowledge gaps and clinical uncertainty in healthcare.
  • Novel analytical methods applied to existing data hold significant potential for CER, particularly in cancer care.

Purpose of the Study:

  • To identify and characterize challenges hindering the improvement, acceleration, and implementation of cancer CER.
  • To explore strategies for enhancing the efficiency and acceptance of cancer CER findings.

Main Methods:

  • Literature review and semistructured interviews with 41 cancer CER researchers from the DEcIDE Cancer CER Consortium.
  • Development of an ontology categorizing cancer CER data sets based on strengths, weaknesses, and utility.

Main Results:

  • Identified key challenges in cancer CER, including the need to accelerate research and promote acceptance of findings.
  • Highlighted the necessity of transcending disciplinary silos through multidisciplinary collaboration for robust cancer CER.
  • Characterized various data sets used in cancer CER, detailing their utility and limitations.

Conclusions:

  • Accelerating cancer CER and ensuring acceptance requires integrating diverse expertise and perspectives.
  • Recommendations include systematic measure identification, rigorous study designs, policy solutions for data issues, and standardized data security protocols.